Skip to main content
. 2017 Dec 21;7:18000. doi: 10.1038/s41598-017-18177-1

Figure 1.

Figure 1

Design and production of the OVX313-containing L2 antigens. (A) Scheme of the PfTrx-L2-OVX313 construct. (B) SDS-PAGE analysis under reducing (+β-mercaptoethanol; +βmet) conditions of the total lysate from IPTG-induced E. coli cells overexpressing the PfTrx-L2-OVX313 antigen (I) and of the flow-through fraction (FT) obtained after heparin chromatography (see Fig. S2 for SDS-PAGE data on additional intermediate samples). The pool of salt-eluted, heparin-purified fractions (HP) electrophoresed under reducing (+βmet) or non-reducing (−βmet) conditions is shown in the last two lanes. Lanes I and FT were cropped from a single gel (see Fig. S7A for a full-length gel image); lanes labeled HP represent the results of single-sample SDS-PAGE analyses separately performed on the post-heparin pool. (C) Size-exclusion chromatography (SEC) analysis (see ‘Methods’ for details) carried out on heparin-purified PfTrx-L2-OVX313; Ve: excluded volume. The corresponding data for the PfTrx-lacking, L2-OVX313 construct are shown in panels D, E (see Fig. S7B for a full-length image of the gel from which lanes I and FT were extracted) and F, respectively.